Press releases
- Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
- Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
- Jacobio Pharma Announces 2023 Annual Results
- Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
- Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
More ▼
Key statistics
On Friday, Jacobio Pharmaceuticals Group Co Ltd (1167:HKG.HS) closed at 1.86, 34.78% above the 52 week low of 1.38 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.96 |
---|---|
High | 2.00 |
Low | 1.85 |
Bid | 1.86 |
Offer | 1.88 |
Previous close | 1.96 |
Average volume | 776.70k |
---|---|
Shares outstanding | 791.76m |
Free float | 442.77m |
P/E (TTM) | -- |
Market cap | 1.55bn HKD |
EPS (TTM) | -0.5019 HKD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼